All In Biotech

Drug Trial Radar · NCT04950075

Study of INBRX-109 in Conventional Chondrosarcoma

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

206

Actual

Start

Sep 23, 2021

Primary completion

Sep 30, 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Inhibrx Biosciences, IncIndustry
Sponsor type
Industry
First posted
Jul 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Conditions

  • Conventional Chondrosarcoma

Interventions

  • INBRX-109Drug

    Tetravalent DR5 Agonist Antibody

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival per RECISTv1.1 by real time IRR comparing INBRX-109 and placeboTime frame: 3 years

Locations

68 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center

    Phoenix, Arizona

  • Precision NextGen Oncology & Research Center

    Beverly Hills, California

  • University of California, San Francisco (UCSF)

    San Francisco, California

  • Sarcoma Oncology Center

    Santa Monica, California

  • University of Colorado

    Denver, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center

    Chicago, Illinois

  • Rush Cancer Center

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Johns Hopkins

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School of Medicine - St. Louis

    St Louis, Missouri

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Norris Cotton Cancer Center

    Lebanon, New Hampshire

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Columbia University

    New York, New York

  • Duke University

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Oklahoma - Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Oregon Health & Science University (OHSU) Knight Cancer Institute

    Portland, Oregon

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Washington

    Seattle, Washington

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Chris O'Brien Lifehouse

    Camperdown, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Australia

  • Centre Oscar Lambret

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • AP-HM - Hôpital de la Timone

    Marseille, France

  • ICM - Institut Regional du Cancer de Montpellier

    Montpellier, France

  • Centre Antoine-Lacassagne

    Nice, France

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.